Home > “Compound 19”

molecules of the month

<< Back to April

“Compound 19”

Recent Publication

JAK1/TYK2-selective dual kinase inhibitor

oral activity in arthritis model

from SBDD of prior internal matter

Bioorg. Med. Chem. Lett., Mar. 31, 2020

Pfizer, Cambridge, MA and Groton, CT

“Compound 19” is a JAK1/TYK2 dual kinase inhibitor from Pfizer, related to its clinical JAK1/TYK2 dual inhibitor, brepocitinib, in Ph. II for a variety of inflammatory diseases. The cyclopropyl amide…

this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.

LEARN MORE

“Compound 19”

this content is exclusive to Premium members

this content is exclusive to
Premium members